In last trading session, Regulus Therapeutics Inc. (NASDAQ:RGLS) saw 1,559,179 shares changing hands with its beta currently measuring 1.99. Company’s recent per share price level of $0.66 trading at $0.08 or 13.79% at ring of the bell on the day assigns it a market valuation of $25.85 Million. That closing price of RGLS’s stock is at a discount of -163.64% from its 52-week high price of $1.74 and is indicating a premium of 36.36% from its 52-week low price of $0.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 415.48 Million shares which gives us an average trading volume of 469.49 Million if we extend that period to 3-months.
For Regulus Therapeutics Inc. (RGLS), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.7. Splitting up the data highlights that, out of 4 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 1 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.12 in the current quarter.
Regulus Therapeutics Inc. (NASDAQ:RGLS) trade information
Upright in the green today for gaining 13.79%, in the last five days RGLS remained trading in the green while hitting it’s week-highest on Thursday, Nov 19 when the stock touched $0.689 price level, adding 4.21% to its value on the day. Regulus Therapeutics Inc.’s shares saw a change of -25.84% in year-to-date performance and have moved 27.66% in past 5-day. Regulus Therapeutics Inc. (NASDAQ:RGLS) showed a performance of 29.39% in past 30-days. Number of shares sold short was 932.3 Million shares which calculate 1.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $1 to the stock, which implies a rise of 51.52% to its current value. Analysts have been projecting $0.5 as a low price target for the stock while placing it at a high target of $1.5. It follows that stock’s current price would jump +127.27% in reaching the projected high whereas dropping to the targeted low would mean a loss of -24.24% for stock’s current value.
Regulus Therapeutics Inc. (RGLS) estimates and forecasts
Statistics highlight that Regulus Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -3.65% of value to its shares in past 6 months, showing an annual growth rate of -36.11% while that of industry is 15.6. Apart from that, the company came raising its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to increase by 47.8% in the current quarter and calculating 44% increase in the next quarter. This year revenue growth is estimated to drop -8.4% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $3.01 Million for the same. And 2 analysts are in estimates of company making revenue of $2.5 Million in the next quarter that will end in March 01, 2021. Company posted $18Million and $3.34 Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 16622.2% while estimating it to be -25.1% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 41.3% during past 5 years. In 2020, company’s earnings growth rate is likely to be around 80.7% while estimates for its earnings growth in next 5 years are of 39.6%
Regulus Therapeutics Inc. (NASDAQ:RGLS)’s Major holders
Insiders are in possession of 4.42% of company’s total shares while institution are holding 23.01% percent of that, with stock having share float percentage of 24.07%. Investors also watch the number of corporate investors in a company very closely, which is 32 institutions for Regulus Therapeutics Inc. that are currently holding shares of the company. BVF Inc. is the top institutional holder at RGLS for having 3.22 Million shares of worth $1.65 Million. And as of September 29, 2020, it was holding 8.22% of the company’s outstanding shares.
The second largest institutional holder is NEA Management Company, LLC, which was holding about 2.05 Million shares on September 29, 2020. The number of shares represents firm’s hold over 5.24% of outstanding shares, having a total worth of $1.05 Million.
On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of June 29, 2020, the former fund manager was holding 32503 shares of worth $22.15 Thousand or 0.08% of the total outstanding shares. The later fund manager was in possession of 30.17 Thousand shares on August 30, 2020, making its stake of worth around $15.99 Thousand in the company or a holder of 0.08% of company’s stock.